drug
laromestrocel
Phase 2updated 6mo agoby $LGVN Longeveron Inc.
Phase 2community read0 votes
indications
indications
Alzheimer's Disease
all catalysts(0)
nothing on the calendar yet
News(4)
- Significant stock movers of September: Viking soars, Longeveron slidesViking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.biospace · 1mo ago
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drugUltragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.biopharma_dive · 1mo ago
- Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trialWith just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a strategic review after the failure of a cardiovascular study.biospace · 2mo ago
- Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.fiercebiotech · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that